Maranchie, Jodi K.

Belzutifan for Renal Cell Carcinoma in von Hippel–Lindau Disease

Jonasch, E., Donskov, F., Iliopoulos, O., Rathmell, W. K., Narayan, V. K., Maughan, B. L., Oudard, S., Else, T., Maranchie, J. K., Welsh, S. J., et al. (2021) · New England Journal of Medicine

Renal cell carcinoma treatmentCancer, Hypoxia, and Metabolism

Cited by 714

Belzutifan for von Hippel-Lindau disease-associated renal cell carcinoma and other neoplasms (LITESPARK-004): 50 months follow-up from a single-arm, phase 2 study

Srinivasan, R., Iliopoulos, O., Beckermann, K. E., Narayan, V., Maughan, B. L., Oudard, S., Else, T., Maranchie, J. K., Iversen, A. B., Cornell, J., et al. (2025) · The Lancet Oncology

Renal cell carcinoma treatmentCancer, Hypoxia, and Metabolism

Cited by 50

Phase II Study of the Oral HIF-2α Inhibitor MK-6482 for Von Hippel-Lindau Disease-Associated Renal Cell Carcinoma

Jonasch, E., Donskov, F., Iliopoulos, O., Rathmell, W. K., Narayan, V., Maughan, B. L., Oudard, S., Else, T., Maranchie, J. K., Welsh, S. J., et al. (2020) · Journal of Clinical Oncology

Renal cell carcinoma treatmentCancer, Hypoxia, and Metabolism

Cited by 42

Phase 2 study of belzutifan (MK-6482), an oral hypoxia-inducible factor 2α (HIF-2α) inhibitor, for Von Hippel-Lindau (VHL) disease-associated clear cell renal cell carcinoma (ccRCC).

Srinivasan, R., Donskov, F., Iliopoulos, O., Rathmell, W. K., Narayan, V., Maughan, B. L., Oudard, S., Else, T., Maranchie, J. K., Welsh, S. J., et al. (2021) · Journal of Clinical Oncology

Renal cell carcinoma treatmentCancer, Hypoxia, and Metabolism

Cited by 22